ClinicalTrials.gg
CompletedNCT00479713Updated May 16, 2024Results posted

A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED)

A Phase 3 interventional study of ezetimibe (+) simvastatin and Comparator : rosuvastatin calcium in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2024-05-16.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Feb 2007, registered May 2007).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
618
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
12th of 97
618 · median 148
Started
2007
with 15 others
Phase 3
50 of 98
1 open now
Registered
26th of 98
by date
Lead sponsor
55 of 98
Organon and Co

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 12th largest by enrollment of the 97 interventional ones that give a count, is one of 16 that started in 2007, is one of 50 in phase 3, and was the 26th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

This is a multicenter study to evaluate the safety and efficacy of ezetimibe/simvastatin versus rosuvastatin in participants with high cholesterol.

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • High Cholesterol
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is currently taking a statin medication for the treatment of high cholesterol
  • Participant has an LDL-C level that is greater than or equal to 100 mg/dl and less than or equal to 190 mg/dl

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or nursing, or women who intend to become pregnant
  • Participant has any condition, situation, or is currently taking any medication that might pose a risk to the participant or interfere with participation in the study
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
618 participants (actual)

Study arms

  • Experimental
    1

    Arm 1: drug

    Drug: ezetimibe (+) simvastatin · Drug: Comparator: Placebo (unspecified)

  • Active comparator
    2

    Arm 2: active comparator

    Drug: Comparator : rosuvastatin calcium · Drug: Comparator: Placebo (unspecified)

Interventions

  • Drugezetimibe (+) simvastatin

    Drug pages: Ezetimibe · Simvastatin

    ezetimibe/simvastatin 10/20mg. The treatment duration will be 6 weeks.

    Also known as: MK0653A, Vytorin®

  • rosuvastatin 10mg. The treatment duration will be 6 weeks.

  • DrugComparator: Placebo (unspecified)

    rosuvastatin 10mg Placebo. The treatment duration will be 6 weeks.

  • DrugComparator: Placebo (unspecified)

    ezetimibe/simvastatin 10/20mg Placebo. The treatment duration will be 6 weeks.

06

What researchers measure

Primary outcomes

  1. Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) at Study Endpoint After Six Weeks of Treatment

    Percent Change in LDL-C at study endpoint after six weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.

    Time frame: Baseline and 6 weeks

Secondary outcomes

  1. The Percentage of Participants Achieving Designated Low Density Lipoprotein-Cholesterol (LDL-C) Levels After 6 Weeks of Treatment

    The percentage of participants who achieved a target LDL-C goal of \< 100 mg/dL, of \<70 mg/dL, and of \<77 mg/dL at study endpoint after six weeks of treatment. The numerator is the number of participants in a treatment group who achieved a target LDL-C goal and the denominator is the total number of participants within that treatment group.

    Time frame: after 6 weeks of treatment

Other outcomes

  1. Percent Change From Baseline in Total Cholesterol

    Percent change from baseline in total cholesterol at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.

    Time frame: Baseline and 6 weeks

  2. Percent Change From Baseline in Triglycerides.

    Percent change from baseline in triglycerides at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.

    Time frame: Baseline and 6 weeks

  3. Percent Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C)

    Percent change from baseline in HDL-C at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.

    Time frame: Baseline and 6 weeks

  4. Percent Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C)

    Percent change from baseline in non HDL-C at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.

    Time frame: Baseline and 6 weeks

  5. Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C)/High Density Lipoprotein-Cholesterol (HDL-C) Ratio

    Percent change from baseline in LDL-C/HDL-C ratio at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.

    Time frame: Baseline and 6 weeks

  6. Percent Change From Baseline in Total Cholesterol/High Density Lipoprotein-Cholesterol (HDL-C) Ratio

    Percent change from baseline in total cholesterol/HDL-C ratio at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.

    Time frame: Baseline and 6 weeks

  7. Percent Change From Baseline in Apolipoprotein B

    Percent change from baseline in apolipoprotein (Apo) B at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.

    Time frame: Baseline and 6 weeks

  8. Percent Change From Baseline in High-sensitivity C (Hs-C) Reactive Protein

    Percent change from baseline in hs-C reactive protein at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.

    Time frame: Baseline and 6 weeks

07

Results

Posted Jun 10, 2009

Participant flow

Phase IV First Participant In: 31-Mar-2007; Last Participant Last Visit 11-Mar-2008 85 centers worldwide (EX US) Eligible participants include those on a stable dose of one of the following: rosuvastatin 5 mg; simvastatin 20 mg, 40 mg; atorvastatin 10, 20 mg; pravastatin 40 mg; fluvastatin 80 mg.

Participant flow — Overall Study
MilestoneEzetemibe + SimvastatinRosuvastatin
Started314304
Completed301295
Not completed139
Withdrew: Adverse event86
Withdrew: Death10
Withdrew: Lost to follow-up01
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject41

Outcome measures

PrimaryPercent Change in Low Density Lipoprotein-Cholesterol (LDL-C) at Study Endpoint After Six Weeks of Treatment

Percent Change in LDL-C at study endpoint after six weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.

Time frame:
Baseline and 6 weeks
Reported as:
Least squares mean · percent change from baseline
Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) at Study Endpoint After Six Weeks of Treatment
percent change from baselineEzetemibe + SimvastatinRosuvastatin
Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) at Study Endpoint After Six Weeks of Treatment-27.66 (-30.27 to -25.04)-16.94 (-19.61 to -14.28)
Statistical analysis
  • Ezetemibe + Simvastatin vs Rosuvastatin · ANOVA · p = <=0.001 · Mean difference (final values): -10.72 · 95% CI -14.10 to -7.33Model terms: treatment, stratum, baseline (categorized based on quartiles) and center
SecondaryThe Percentage of Participants Achieving Designated Low Density Lipoprotein-Cholesterol (LDL-C) Levels After 6 Weeks of Treatment

The percentage of participants who achieved a target LDL-C goal of \< 100 mg/dL, of \<70 mg/dL, and of \<77 mg/dL at study endpoint after six weeks of treatment. The numerator is the number of participants in a treatment group who achieved a target LDL-C goal and the denominator is the total number of participants within that treatment group.

Time frame:
after 6 weeks of treatment
Reported as:
Number · Percent of participant population
The Percentage of Participants Achieving Designated Low Density Lipoprotein-Cholesterol (LDL-C) Levels After 6 Weeks of Treatment
Percent of participant populationEzetemibe + SimvastatinRosuvastatin
LDL-C <10072.4656.23
LDL-C <7025.2511.11
Statistical analysis
  • Ezetemibe + Simvastatin vs Rosuvastatin · Regression, Logistic · p = <=0.001 · Odds ratio (or): 2.1 · 95% CI 1.5 to 3.0Model terms: treatment, stratum and baseline LDL-C (continuous)
  • Ezetemibe + Simvastatin vs Rosuvastatin · Regression, Logistic · p = <=0.001 · Odds ratio (or): 2.8 · 95% CI 1.8 to 4.4Model terms: treatment, stratum and baseline LDL-C (continuous)
Other pre-specifiedPercent Change From Baseline in Total Cholesterol

Percent change from baseline in total cholesterol at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.

Time frame:
Baseline and 6 weeks
Reported as:
Least squares mean · percent change from baseline
Percent Change From Baseline in Total Cholesterol
percent change from baselineEzetemibe + SimvastatinRosuvastatin
Percent Change From Baseline in Total Cholesterol-17.53 (-19.36 to -15.71)-10.33 (-12.19 to -8.47)
Statistical analysis
  • Ezetemibe + Simvastatin vs Rosuvastatin · ANOVA · p = <=0.001 · Mean difference (final values): -7.20 · 95% CI -9.56 to -4.84Model terms: treatment, stratum, baseline (categorized based on quartiles) and center
Other pre-specifiedPercent Change From Baseline in Triglycerides.

Percent change from baseline in triglycerides at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.

Time frame:
Baseline and 6 weeks
Reported as:
Median · percent change from baseline
Percent Change From Baseline in Triglycerides.
percent change from baselineEzetemibe + SimvastatinRosuvastatin
Percent Change From Baseline in Triglycerides.-11.00 (-15.25 to -6.80)-5.26 (-9.92 to -1.17)
Statistical analysis
  • Ezetemibe + Simvastatin vs Rosuvastatin · Nonparametric ANOVA · p = 0.056 · Median difference (final values): -5.06 · 95% CI -9.56 to -0.30The median difference between treatments is based on the Hodges-Lehmann estimates of shift with a corresponding distribution-free Confidence Interval (CI) based on Wilcoxon's rank.
Other pre-specifiedPercent Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C)

Percent change from baseline in HDL-C at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.

Time frame:
Baseline and 6 weeks
Reported as:
Least squares mean · percent change from baseline
Percent Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C)
percent change from baselineEzetemibe + SimvastatinRosuvastatin
Percent Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C)2.12 (0.34 to 3.89)3.03 (1.22 to 4.85)
Statistical analysis
  • Ezetemibe + Simvastatin vs Rosuvastatin · ANOVA · p = 0.433 · Mean difference (final values): -0.92 · 95% CI -3.21 to 1.38Model terms: treatment, stratum, baseline (categorized based on quartiles) and center.
Other pre-specifiedPercent Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C)

Percent change from baseline in non HDL-C at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.

Time frame:
Baseline and 6 weeks
Reported as:
Least squares mean · percent change from baseline
Percent Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C)
percent change from baselineEzetemibe + SimvastatinRosuvastatin
Percent Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C)-23.42 (-25.81 to 21.03)-14.01 (-16.46 to -11.57)
Statistical analysis
  • Ezetemibe + Simvastatin vs Rosuvastatin · ANOVA · p = <=0.001 · Mean difference (final values): -9.41 · 95% CI -12.50 to -6.31Model terms: treatment, stratum, baseline (categorized based on quartiles) and center.
Other pre-specifiedPercent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C)/High Density Lipoprotein-Cholesterol (HDL-C) Ratio

Percent change from baseline in LDL-C/HDL-C ratio at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.

Time frame:
Baseline and 6 weeks
Reported as:
Least squares mean · percent change from baseline
Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C)/High Density Lipoprotein-Cholesterol (HDL-C) Ratio
percent change from baselineEzetemibe + SimvastatinRosuvastatin
Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C)/High Density Lipoprotein-Cholesterol (HDL-C) Ratio-27.41 (-30.42 to -24.40)-17.82 (-20.89 to -14.75)
Statistical analysis
  • Ezetemibe + Simvastatin vs Rosuvastatin · ANOVA · p = <=0.001 · Mean difference (final values): -9.59 · 95% CI -13.49 to -5.69Model terms: treatment, stratum, baseline (categorized based on quartiles) and center.
Other pre-specifiedPercent Change From Baseline in Total Cholesterol/High Density Lipoprotein-Cholesterol (HDL-C) Ratio

Percent change from baseline in total cholesterol/HDL-C ratio at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.

Time frame:
Baseline and 6 weeks
Reported as:
Least squares mean · percent change from baseline
Percent Change From Baseline in Total Cholesterol/High Density Lipoprotein-Cholesterol (HDL-C) Ratio
percent change from baselineEzetemibe + SimvastatinRosuvastatin
Percent Change From Baseline in Total Cholesterol/High Density Lipoprotein-Cholesterol (HDL-C) Ratio-17.76 (-19.94 to -15.57)-11.51 (-13.74 to -9.28)
Statistical analysis
  • Ezetemibe + Simvastatin vs Rosuvastatin · ANOVA · p = <=0.001 · Mean difference (final values): -6.25 · 95% CI -9.07 to -3.43Model terms: treatment, stratum, baseline (categorized based on quartiles) and center.
Other pre-specifiedPercent Change From Baseline in Apolipoprotein B

Percent change from baseline in apolipoprotein (Apo) B at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.

Time frame:
Baseline and 6 weeks
Reported as:
Least squares mean · percent change from baseline
Percent Change From Baseline in Apolipoprotein B
percent change from baselineEzetemibe + SimvastatinRosuvastatin
Percent Change From Baseline in Apolipoprotein B-17.87 (-20.05 to -15.70)-9.77 (-11.99 to -7.55)
Statistical analysis
  • Ezetemibe + Simvastatin vs Rosuvastatin · ANOVA · p = <=0.001 · Mean difference (final values): -8.11 · 95% CI -10.91 to -5.30Model terms: treatment, stratum, baseline (categorized based on quartiles) and center
Other pre-specifiedPercent Change From Baseline in High-sensitivity C (Hs-C) Reactive Protein

Percent change from baseline in hs-C reactive protein at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \*100.

Time frame:
Baseline and 6 weeks
Reported as:
Median · percent change from baseline
Percent Change From Baseline in High-sensitivity C (Hs-C) Reactive Protein
percent change from baselineEzetemibe + SimvastatinRosuvastatin
Percent Change From Baseline in High-sensitivity C (Hs-C) Reactive Protein-8.33 (-16.67 to 0.00)0.00 (-7.14 to 6.25)
Statistical analysis
  • Ezetemibe + Simvastatin vs Rosuvastatin · Nonparametric ANOVA · p = 0.172 · Mean difference (final values): -6.67 · 95% CI -16.67 to 2.87The median difference between treatments is based on the Hodges-Lehmann estimates of shift with a corresponding distribution-free CI based on Wilcoxon's rank

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ezetemibe + Simvastatin———
Rosuvastatin———
Most frequent serious events
Most frequent serious events
EventEzetemibe + SimvastatinRosuvastatin
Chest painGeneral disorders0/3122/304
Epileptic seizureNervous system disorders0/3121/304
Skin eruptionSkin and subcutaneous tissue disorders0/3121/304
In-stent arterial restenosisInjury, poisoning and procedural complications0/3121/304
CholangitisHepatobiliary disorders1/3120/304
Accidental overdoseInjury, poisoning and procedural complications1/3120/304
Subarachnoid hemorrhageNervous system disorders1/3120/304
Most frequent other events
Showing 10 of 50
Most frequent other events
EventEzetemibe + SimvastatinRosuvastatin
DiarrhoeaGastrointestinal disorders3/3121/304
DyspepsiaGastrointestinal disorders3/3121/304
MyalgiaMusculoskeletal and connective tissue disorders3/3122/304
Abdominal painGastrointestinal disorders2/3122/304
NauseaGastrointestinal disorders2/3120/304
VomittingGastrointestinal disorders2/3120/304
BronchitisInfections and infestations2/3120/304
Abdominal pain upperGastrointestinal disorders1/3121/304
Dry mouthGastrointestinal disorders0/3121/304
AstheniaGeneral disorders0/3121/304

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ezetemibe + SimvastatinRosuvastatinTotal
Mean63.2 (38 to 82)63.1 (27 to 80)63.15 (27 to 82)
Sex: Female, Male
Sex: Female, Male(Participants)Ezetemibe + SimvastatinRosuvastatinTotal
Female129119248
Male185185370
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Ezetemibe + SimvastatinRosuvastatinTotal
White314302616
Black022
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ezetemibe + SimvastatinRosuvastatinTotal
Hispanic or Latino374380
Not Hispanic or Latino277261538
Apolipoprotein B
Apolipoprotein B(mg/dL)Ezetemibe + SimvastatinRosuvastatinTotal
Median1.20 ± 0.201.18 ± 0.211.19 ± 0.21
C Reactive Protein
C Reactive Protein(mg/dL)Ezetemibe + SimvastatinRosuvastatinTotal
Median0.16 ± 0.260.15 ± 0.260.16 ± 0.26
High Density Lipoprotein-Cholesterol
High Density Lipoprotein-Cholesterol(mg/dL)Ezetemibe + SimvastatinRosuvastatinTotal
Mean1.43 ± 0.371.43 ± 0.361.43 ± 0.36
Low Density Lipoprotein-Cholesterol (LDL-C)
Low Density Lipoprotein-Cholesterol (LDL-C)(mg/dL)Ezetemibe + SimvastatinRosuvastatinTotal
Mean3.21 ± 0.423.24 ± 0.443.23 ± 0.43

5 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Farnier M, Averna M, Missault L, Vaverkova H, Viigimaa M, Massaad R, Vandormael K, Johnson-Levonas AO, Brudi P. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. Int J Clin Pract. 2009 Apr;63(4):547-59. doi: 10.1111/j.1742-1241.2009.02022.x. Epub 2009 Feb 16. PubMed 19222610 ↗
  • Averna M, Missault L, Vaverkova H, Farnier M, Viigimaa M, Dong Q, Shah A, Johnson-Levonas AO, Taggart W, Brudi P. Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome. Diab Vasc Dis Res. 2011 Oct;8(4):262-70. doi: 10.1177/1479164111418136. Epub 2011 Aug 22. PubMed 21859750 ↗
  • Viigimaa M, Vaverkova H, Farnier M, Averna M, Missault L, Hanson ME, Dong Q, Shah A, Brudi P. Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency. Lipids Health Dis. 2010 Nov 4;9:127. doi: 10.1186/1476-511X-9-127. PubMed 21050476 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2007 to primary completion in Mar 2008, 13 months.

Results were first posted in Jun 2009, 1 year 3 months after primary completion.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 13 months is below that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2007
First posted
May 28, 2007
StartActual
Feb 1, 2007
Primary completionActual
Mar 1, 2008
CompletionActual
Mar 1, 2008
Results first posted
Jun 10, 2009
Last update
May 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00479713
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
May 28, 2007
Start date
Feb 1, 2007
Primary completion
Mar 1, 2008
Completion
Mar 1, 2008
Results posted
Jun 10, 2009
Last update
May 16, 2024

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ezetimibe · Simvastatin

Start the discussion